Skip to content
Home/Companies/Pharma/tranScrip
tranScrip

tranScrip

Pharma·UK·Active·5yr hold
Entry
2021
Hold
5yr
Status
Active

Who owns tranScrip?

tranScrip is a British Pharma company, currently owned by Palatine Private Equity since 2021.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Palatine Private Equity
Investor
Palatine Private Equity
Palatine Impact Fund II · 2023 · Impact

Key facts

HQUK
SectorPharma
Websitetranscrip-group.com

More from Palatine Impact Fund II

Other portfolio companies in the same fund.

Isle Utilities
Isle Utilities
Active
Business ServicesUK· 2024
The MOLE Clinic
The MOLE Clinic
Active
HealthcareUK· 2024
Papilo
Papilo
Active
Business ServicesUK· 2023
Cura Terrae
Cura Terrae
Active
Business ServicesUK· 2022
Inclusive Employers
Inclusive Employers
Active
Business ServicesUK· 2022

More PE-backed in Pharma

Comparable pharma deals from other GPs.

Abacus Pharmaceuticals
Abacus Pharmaceuticals
Active
The Carlyle GroupUS
AdipoPharma
AdipoPharma
Active
Capital Grand EstFrance
Advantice Health
Advantice Health
Active
TA AssociatesUS
Alcala Farma
Active
Advent InternationalSpain
Alvogen
Alvogen
Active
CVC Capital Partners
Anovo
Anovo
Active
ArdianUS

Questions

Who owns tranScrip?

tranScrip is currently owned by Palatine Private Equity, through Palatine Impact Fund II, since 2021.

When did Palatine Private Equity acquire tranScrip?

Palatine Private Equity acquired tranScrip in 2021.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue